ENTX
Entera Bio Ltd.
There isn't enough reported data to score ENTX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ENTX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
ENTX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ENTX PE Valuation
ENTX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ENTX Forward outlook
There aren't enough analyst estimates for ENTX to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ENTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.38 | -$0.13 |
| Q2 2026 | -$0.34 | -$0.08 |
| Q1 2026 | -$0.26 | $0.00 |
| Q4 2025 | -$0.25 | $0.00 |
| Q3 2025 | -$0.25 | +$0.01 |
| Q2 2025 | -$0.26 | $0.00 |
| Q1 2025 | -$0.26 | +$0.02 |
| Q4 2024 | -$0.25 | +$0.06 |
ENTX is still losing money, but far less than before: $0.38 per share over the past year, against $0.92 at its worst in late 2019.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ENTX on earnings quality, reporting a profit while its opponent remains loss making.
ENTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2022 | $14K | -92% |
| Q3 2022 | $8K | -94% |
| Q2 2022 | $44K | -60% |
| Q1 2022 | $68K | -57% |
| Q4 2021 | $165K | -25% |
| Q3 2021 | $140K | +180% |
| Q2 2021 | $109K | +110% |
| Q1 2021 | $157K | +274% |
ENTX's revenue has slid since its 2020 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -6102% | N/A |
| Q4 2024 | -2850% | N/A |
| Q3 2024 | -7193% | N/A |
| Q2 2024 | -3798% | N/A |
| Q4 2022 | -21914% | -19413 points |
| Q3 2022 | -35813% | -38113 points |
| Q2 2022 | -7384% | -5026 points |
| Q1 2022 | -5640% | -4150 points |
ENTX's operating margin was −6102% last quarter, up 15812 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ENTX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
ENTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.4M | -$4.9M |
| Q2 2026 | -$3.5M | -$1.8M |
| Q1 2026 | -$3.1M | -$1.7M |
| Q4 2025 | -$1.9M | -$390K |
| Q3 2025 | -$2.5M | -$391K |
| Q2 2025 | -$1.7M | -$325K |
| Q1 2025 | -$1.4M | +$450K |
| Q4 2024 | -$1.5M | +$1.2M |
ENTX has burned cash in almost every quarter: −$16M over the past year, against −$7M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ENTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
ENTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +188% | +94.6M shares |
| 1 year | +208% | +98M shares |
| 3 years | +403% | +116M shares |
| 5 years | +487% | +120M shares |
| Available history | +1104% | +133M shares |
ENTX has 145M diluted shares, up 208% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ENTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ENTX Net Leverage
ENTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ENTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.7 | Neutral |
| Stochastic | 58.6 | Neutral |
ENTX's weekly RSI is 67 (neutral) and its Stochastic is 59 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ENTX PE vs Healthcare Sector
ENTX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ENTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.93 | 9.9% above |
| 20 week MA | $2.73 | 18% above |
| 50 week MA | $1.94 | 66% above |
| 100 week MA | $2.03 | 59% above |
| 200 week MA | $1.65 | 95% above |
ENTX is in an uptrend: it's above all five of its weekly moving averages, and 95% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
ENTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.01 | $1.07 | -47% |
| 2021 | $1.07 | $3.05 | +185% |
| 2022 | $3.05 | $0.55 | -82% |
| 2023 | $0.55 | $0.60 | +9.1% |
| 2024 | $0.60 | $2.15 | +258% |
| 2025 | $2.15 | $1.72 | -20% |
| 2026 YTD | $1.72 | $3.22 | +87% |
ENTX has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.